Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the appointment of Dr. Robert Panting as General Manager of Rentschler ATMP[*] Ltd. This center of excellence is in Stevenage, UK, Europe's largest cell and gene therapy hub. It was set up to address the gap in capacity and support for early-stage innovators in cell and gene therapy. In this position, Dr. Panting will manage all operations at the site.
“I am delighted to welcome Dr. Robert Panting to the Rentschler team. With his great experience running complex operations and setting up the structures needed for a new site, he is the ideal choice to manage our cell and gene therapy facility,” said Dr. Frank Mathias, CEO of Rentschler Biopharma. “We are excited by the great progress we have made since launching our plans in the UK earlier this year and look forward to establishing this facility for the state-of-the-art manufacturing of viral vectors for clinical supply. Dr. Panting’s leadership will be a critical aspect of driving this project to be client-ready for cGMP manufacturing.”
Dr. Panting, General Manager of Rentschler ATMP, added: “I am honored to join the Rentschler team and to manage operations at the company’s exciting undertaking in ATMP manufacturing. Rentschler Biopharma is highly regarded in the industry. I look forward to ensuring that the new site provides the reliable, client-focused, high quality service for which the company is known. I also look forward to contributing to moving the business into new technologies and offerings. I am thrilled by the strong interest we have already seen for our ATMP services.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!